# Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
Canonical URL: https://biopharmsignal.com/news/BRNS/barinthus-bio-announces-strategic-focus-in-immunology-and-inflammation-iandi-and-provides-a-financial-update
Ticker: BRNS
Company: Barinthus Biotherapeutics
Source: Barinthus Biotherapeutics
Published: 2025-01-10 13:00 EST
Original Source URL: https://investors.barinthusbio.com
## Summary

Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025 Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identified Extending the cash runway to the start of 2027 by reducing costs, including an approximate 65%

## Article Body
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025 Postponing further clinical development of VTP-300 in chronic hepatitis B (CHB) until a partner is identified Extending the cash runway to the start of 2027 by reducing costs, including an approximate 65%
## Recent Company News
- 2026-04-30 11:30 EST — [Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments](https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-first-quarter-2026-financial-results-and-updates-on-corporate-developments) — Source: Barinthus Biotherapeutics
- 2026-03-13 12:00 EST — [Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments](https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-full-year-2025-financial-results-and-updates-on-corporate-developments) — Source: Barinthus Biotherapeutics
- 2025-12-10 13:00 EST — [Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease](https://biopharmsignal.com/news/BRNS/barinthus-bio-announces-update-on-phase-1-avalon-clinical-trial-of-vtp-1000-for-the-treatment-of-celiac-disease) — Source: Barinthus Biotherapeutics
- 2025-11-07 12:30 EST — [Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments](https://biopharmsignal.com/news/BRNS/barinthus-bio-reports-third-quarter-2025-financial-results-and-updates-on-corporate-developments) — Source: Barinthus Biotherapeutics
- 2025-09-30 12:01 EST — [Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases](https://biopharmsignal.com/news/BRNS/barinthus-biotherapeutics-to-combine-with-clywedog-therapeutics-to-target-metabolic-and-autoimmune-diseases) — Source: Barinthus Biotherapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)